Skip to main content
Erschienen in: Tumor Biology 11/2014

01.11.2014 | Research Article

Armc8 expression was elevated during atypia-to-carcinoma progression and associated with cancer development of breast carcinoma

verfasst von: Chuifeng Fan, Yang Zhao, Xiaoyun Mao, Yuan Miao, Xuyong Lin, Guiyang Jiang, Xiupeng Zhang, Qiang Han, Lan Luan, Enhua Wang

Erschienen in: Tumor Biology | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

Armadillo repeat-containing protein 8 (Armc8) is a key factor to regulate cell membrane adhesion complex through promoting α-catenin degradation. However, its expression and function in human malignant tumors are largely unknown. Here, we present our study investigating Armc8 expression in tumor and non-tumor breast tissues including 45 normal epithelia, 53 lesions of hyperplasia with or without dysplasia, 22 benign tumors, and 92 carcinomas including 28 carcinomas in situ and 64 infiltrating carcinomas using immunohistochemistry (IHC) and Western blotting study. Armc8 expression was detected mainly in the cytoplasm with occasional membrane immunostaining. The positive rate of Armc8 expression in normal breast epithelia (8.9 %, four out of 45) was very low. No significant difference was found between Armc8 expression in usual ductal hyperplasia (UDH) (11.1 %, two out of 18), benign breast tumors including intraductal papilloma (10.0 %, one out of 10) and fibroadenoma (8.3 %, one out of 12), and normal breast epithelia (p > 0.05). Elevated expression of Armc8 was found in breast epithelia with dysplasia (24.0 %, six out of 25) compared to that in normal breast epithelia, UDH, and benign breast tumors (p < 0.05). Armc8 expression in breast carcinoma including breast carcinoma in situ (10/28, 35.7 %), infiltrating ductal carcinoma (60.7 %, 34/56), and infiltrating lobular carcinoma (50.0 %, 4/8) was higher than that in normal breast epithelia, UDH, benign breast tumors, and breast epithelia with dysplasia (p < 0.05). The highest expression of Armc8 was found in infiltrating breast carcinoma (59.4 %, 38/64) compared to all the other breast tissues. Higher Armc8 expression was found to be linked to lymph node metastasis and advanced tumor–node–metastasis (TNM) stages (III + IV) in infiltrating breast carcinoma (p < 0.05). We further confirmed Armc8 expression in breast epithelial cell line MCF10A and breast carcinoma cell lines including MCF-7, MDA-MB-231, and ZR751 using Western blotting and immunofluorescent study. These results indicate that the elevated expression of Armc8 may be involved in carcinogenesis including atypia-to-carcinoma progression and cancer development of breast carcinoma.
Literatur
1.
Zurück zum Zitat Takeyuki S, Atsuhisa U, Nobuaki K, et al. Proteasome-dependent degradation of α-catenin is regulated by interaction with Armc8α. Biochem. 2008;411:581–91.CrossRef Takeyuki S, Atsuhisa U, Nobuaki K, et al. Proteasome-dependent degradation of α-catenin is regulated by interaction with Armc8α. Biochem. 2008;411:581–91.CrossRef
2.
Zurück zum Zitat Nawrocki B, Polette M, Van Hengel J, et al. Cytoplasmic redistribution of E-cadherin-catenin adhesion complex is associated with down-regulated tyrosine phosphorylation of E-cadherin in human bronchopulmonary carcinomas. Am J Pathol. 1998;153(5):1521–30.PubMedCentralPubMedCrossRef Nawrocki B, Polette M, Van Hengel J, et al. Cytoplasmic redistribution of E-cadherin-catenin adhesion complex is associated with down-regulated tyrosine phosphorylation of E-cadherin in human bronchopulmonary carcinomas. Am J Pathol. 1998;153(5):1521–30.PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Sadot E, Conacci-Sorrell M, Zhurinsky J, et al. Regulation of S33/S37 phosphorylated β-Catenin in normal and transformed cells. J Cell Sci. 2002;115(13):2771–80.PubMed Sadot E, Conacci-Sorrell M, Zhurinsky J, et al. Regulation of S33/S37 phosphorylated β-Catenin in normal and transformed cells. J Cell Sci. 2002;115(13):2771–80.PubMed
4.
Zurück zum Zitat Alan W, Clayton Y, Christopher R, et al. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis. 2008;25(6):621–8.CrossRef Alan W, Clayton Y, Christopher R, et al. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis. 2008;25(6):621–8.CrossRef
5.
Zurück zum Zitat Somesh B, Suresh K. Molecular mechanisms controlling E-cadherin expression in breast cancer. Biochem Biophys Res Commun. 2009;384(1):6–11.CrossRef Somesh B, Suresh K. Molecular mechanisms controlling E-cadherin expression in breast cancer. Biochem Biophys Res Commun. 2009;384(1):6–11.CrossRef
6.
Zurück zum Zitat Liu Y, Wang Y, Zhang Y, et al. Abnormal expression of p120-catenin, E-cadherin, and small GTPases is significantly associated with malignant phenotype of human lung cancer. Lung Cancer. 2009;63(3):375–82.PubMedCrossRef Liu Y, Wang Y, Zhang Y, et al. Abnormal expression of p120-catenin, E-cadherin, and small GTPases is significantly associated with malignant phenotype of human lung cancer. Lung Cancer. 2009;63(3):375–82.PubMedCrossRef
7.
Zurück zum Zitat Travis W, Muller-Hermelink H, Harris C. World Health Organization classification of tumors: pathology and genetics of tumors of the female reproduction system. Lyon: IARC Press; 2004. Travis W, Muller-Hermelink H, Harris C. World Health Organization classification of tumors: pathology and genetics of tumors of the female reproduction system. Lyon: IARC Press; 2004.
8.
Zurück zum Zitat Carlson R, Allred C, Anderson B, et al. NCCN guidelines for patients: breast cancer. 2010. Carlson R, Allred C, Anderson B, et al. NCCN guidelines for patients: breast cancer. 2010.
9.
Zurück zum Zitat Fan C, Yu J, Liu Y, et al. Increased NDRG1 expression is associated with advanced T stages and poor vascularization in non-small cell lung cancer. Pathol Oncol Res. 2012;18(3):549–56.PubMedCrossRef Fan C, Yu J, Liu Y, et al. Increased NDRG1 expression is associated with advanced T stages and poor vascularization in non-small cell lung cancer. Pathol Oncol Res. 2012;18(3):549–56.PubMedCrossRef
10.
Zurück zum Zitat Nobuaki K, Jun Y, Atsuhisa U, et al. RanBPM, muskelin, p48EMLP, p44CTLH, and the armadillo-repeat proteins ARMC8α and ARMC8β are components of the CTLH complex. Gene. 2007;396:236–47.CrossRef Nobuaki K, Jun Y, Atsuhisa U, et al. RanBPM, muskelin, p48EMLP, p44CTLH, and the armadillo-repeat proteins ARMC8α and ARMC8β are components of the CTLH complex. Gene. 2007;396:236–47.CrossRef
11.
Zurück zum Zitat Koji T, Atsuhisa U, Takeyuki S, et al. Armadillo repeat containing 8α binds to HRS and promotes HRS interaction with ubiquitinated proteins. Open Biochem J. 2010;4:1–8.CrossRef Koji T, Atsuhisa U, Takeyuki S, et al. Armadillo repeat containing 8α binds to HRS and promotes HRS interaction with ubiquitinated proteins. Open Biochem J. 2010;4:1–8.CrossRef
12.
Zurück zum Zitat Bai M, Agnantis N, Kamina S, et al. In vivo cell kinetics in breast carcinogenesis. Breast Cancer Res. 2011;3:276–83.CrossRef Bai M, Agnantis N, Kamina S, et al. In vivo cell kinetics in breast carcinogenesis. Breast Cancer Res. 2011;3:276–83.CrossRef
13.
Zurück zum Zitat Arpino G, Laucirica R, Elledge R. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med. 2005;143:446–57.PubMedCrossRef Arpino G, Laucirica R, Elledge R. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med. 2005;143:446–57.PubMedCrossRef
14.
Zurück zum Zitat Steinman S, Wang J, Bourne P, et al. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci. 2007;37:127–34.PubMed Steinman S, Wang J, Bourne P, et al. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci. 2007;37:127–34.PubMed
15.
Zurück zum Zitat Liu T, Niu Y, Yu Y, et al. Increased gamma-tubulin expression and P16INK4A promoter methylation occur together in preinvasive lesions and carcinomas of the breast. Ann Oncol. 2009;20:441–8.PubMedCrossRef Liu T, Niu Y, Yu Y, et al. Increased gamma-tubulin expression and P16INK4A promoter methylation occur together in preinvasive lesions and carcinomas of the breast. Ann Oncol. 2009;20:441–8.PubMedCrossRef
16.
Zurück zum Zitat Raynaud C, Hernandez J, Llorca F, et al. DNA damage repair and telomere length in normal breast, preneoplastic lesions, and invasive cancer. Am J Clin Oncol. 2010;33:341–5.PubMedCrossRef Raynaud C, Hernandez J, Llorca F, et al. DNA damage repair and telomere length in normal breast, preneoplastic lesions, and invasive cancer. Am J Clin Oncol. 2010;33:341–5.PubMedCrossRef
Metadaten
Titel
Armc8 expression was elevated during atypia-to-carcinoma progression and associated with cancer development of breast carcinoma
verfasst von
Chuifeng Fan
Yang Zhao
Xiaoyun Mao
Yuan Miao
Xuyong Lin
Guiyang Jiang
Xiupeng Zhang
Qiang Han
Lan Luan
Enhua Wang
Publikationsdatum
01.11.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 11/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2473-0

Weitere Artikel der Ausgabe 11/2014

Tumor Biology 11/2014 Zur Ausgabe

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.